Sr ScientistNovo Nordisk A/SBeijing, Beijing, China (People's Republic)
OC 21.1 - Novel FVIIIa-mimetic molecule with the potential to be the first oral treatment for severe hemophilia A
Sunday, June 23, 202414:45 – 15:00 ICT